Fostering Self-Empowerment in CKD Patients Through Food Choice Mapping

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project maps restaurant food options suitable for CKD patients in Singapore and develops a mobile app, REN DOFOMAP, that uses simple AI to guide food choices. It then trials the app in CKD patients (stages 3B–5) to see if it improves self-empowerment, quality of life, nutritional status, and serum biochemistry. The study also assesses user acceptability and the overall user experience of the app. The aim is to support individualized dietary choices while maintaining cost-effective care and efficient use of dietitian resources.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Are fluent in English. This is necessary to ensure clear communication and understanding of study procedures and materials.
* Adequate proficiency in using smartphone i.e. downloading app, taking photo, completing e-forms within the mobile applications. This is essential for participants to effectively use the mobile application being tested.
* Diagnosed with CKD Stage 3B-5. This targets the specific patient population that the study aims to benefit.

Exclusion Criteria:

* Only fluent in languages other than English. This could hinder effective communication and understanding of the study.
* Diagnosis of cognitive deficit or neurological disorder. These conditions could impair the ability to follow study procedures or provide reliable data.
* Uncontrolled diabetes (HbA1c\>8.5%). This condition could introduce additional health risks and confound study results.
* Recent hypoglycemic episodes. This could pose a safety risk during the study.
* Newly initiated on dialysis or planning for dialysis within the next 6 months. These patients may have rapidly changing health conditions that could affect study outcomes.
* Decompensated liver cirrhosis. This condition could complicate the interpretation of study results.
* Pregnant and lactating. These conditions could introduce additional variables that affect study outcomes.
* Inability to provide consent. This ensures that all participants can legally and ethically participate in the study

Where it's running

• Singapore Institute of Technology
  Singapore, Singapore Recruiting

Study contacts

• Principal investigator: Gary Tung Lin Chiah, MSc, BSc, RD — Singapore Institute of Technology
• Study coordinator: Gary Tung Lin Chiah, MSc, BSc, RD
• Email: gary.chiah@singaporetech.edu.sg
• Phone: +6565925769

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Self-Management Data and Disease Progression in CKD

  This study tests whether patient-recorded self-management data collected via a mobile app can be linked to CKD progression in adults seen at a university hospital.

  Recruiting Chungnam National University Hospital · Daejeon, DJ · NCT07754097

• Enarodustat for Anemia in Non-Dialysis CKD Patients

  This study tests whether enarodustat can help increase hemoglobin safely in adults with CKD who aren’t on dialysis, grouping participants by inflammation level.

  Recruiting Huashan Hospital · Shanghai, Shanghai Municipality · NCT07741279

• Periodontal Health in Rare Kidney Conditions and Controls

  This study tests how common periodontitis is in people with rare kidney disorders and compares it to CKD patients and people without kidney disease.

  Recruiting Institutul Clinic Fundeni · Bucharest · NCT07575347

• AdiaVita regenerative therapy for chronic kidney disease

  This trial tests whether AdiaVita (umbilical cord blood stem cells and exosomes plus glutathione) can improve kidney function in adults with stage 2–4 chronic kidney disease.

  Recruiting Phase 1 Adia Med of Winter Park LLC · Winter Park, Florida · NCT07572890

• HTD1801 vs placebo for kidney protection in type 2 diabetes and CKD

  This trial tests whether HTD1801 can slow kidney decline in adults with type 2 diabetes and chronic kidney disease.

  Recruiting Phase 2 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences · Weifang, Shandong · NCT07496177

• Veverimer for metabolic acidosis in adults with chronic kidney disease.

  This 26-week trial will test whether veverimer can raise bicarbonate levels and improve outcomes in adults with moderate-to-severe CKD and metabolic acidosis.

  Recruiting at 27 sites Phase 3 Renibus Therapeutics, Inc. · Chula Vista, California and 27 other locations · NCT07355062

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.